<DOC>
	<DOCNO>NCT02453061</DOCNO>
	<brief_summary>In study investigator plan include 100 early affected HD patient ( 5 ≤ UHDRS ≤ 40 ) randomize , double-blind , control study 2 center ( France Netherlands ) . Patients receive either triheptanoin 1g/kg body weight per day ( n = 50 ) , control oil ( n = 50 ) 1g/kg body weight per day 6 month follow open label phase use triheptanoin another 6 month . Efficacy triheptanoin evaluate measurement caudate volume use volumetric magnetic resonance imaging brain energy metabolism evaluate ratio inorganic phosphate/phosphocreatine , visual stimulation , use 31P-MRS. Clinical improvement evaluate UHDRS , TFC , PBA-S score well performance neuropsychological battery ; patient quality life evaluate qualitative research method 6 month SF-36 questionnaire treatment ; biological tolerance compliance evaluate routine biochemical blood test , plasma urine measurement triheptanoin oil derivative patient report .</brief_summary>
	<brief_title>A Comparative Phase 2 Study Assessing Efficacy Triheptanoin , Anaplerotic Therapy Huntington 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Huntington Disease</mesh_term>
	<criteria>Positive genetic test CAG repeat length ≥39 HTT gene At least 18 year age Signature inform consent Covered social security UHDRS score 5 40 Ability undergo MRI scan BMI 18 30 Hypersensitivity triheptanoin one excipients Additional major comorbidities History severe head injury Participation another therapeutic trial ( 3 month exclusion period ) For woman childbearing age , absence two form effective contraception ( exception abstinent ) Pregnancy breastfeed Inability understand information protocol Persons deprive liberty judicial administrative decision Adult subject legal protection unable consent Treatment tetrabenazine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>